Protein biomarker immunoassays for sepsis

Technology class

Protein biomarker immunoassays for sepsis

Immunoassay methods and compositions for sepsis-associated protein biomarker detection

Protein biomarker immunoassays for sepsis quantify host-response proteins—most prominently procalcitonin (PCT), but also C-reactive protein, presepsin, pancreatic stone protein, and emerging multi-marker panels—to stratify infection likelihood, guide antibiotic initiation or de-escalation, and support prognostication. Unlike pathogen-directed methods such as M2 multiplex PCR or M3 direct-from-blood detection, these assays interrogate the patient's inflammatory and immune response rather than identifying causative organisms, making them complementary tools for clinical decision-making in suspected sepsis.

Sample typePlasma / serum
Diagnostic questionHost response
Time to result1–8 hours
Lab tierHospital core lab
Filing growth, 2014–23−9.4% a year
Patent holders134
Effective holders51
Commercial products432

Effective holders is the inverse of the HHI (1 ÷ HHI): a measure of how concentrated patent ownership is in this class.

Technology mechanism

The dominant assay format employs sandwich immunoassay architecture on automated laboratory analyzers: a capture antibody immobilized on a solid phase (microparticle, bead, or coated well) binds the target protein, followed by a labeled detection antibody that generates a measurable signal proportional to analyte concentration. Signal generation varies by platform—electrochemiluminescence on Roche Elecsys systems, enzyme-linked fluorescence on bioMérieux VIDAS, chemiluminescence on Beckman Coulter Access and DiaSorin LIAISON, and turbidimetric or latex-enhanced methods on clinical chemistry analyzers from vendors including Diazyme and DiaSys. Procalcitonin assays typically measure concentrations from 0.02–0.05 ng/mL (functional sensitivity) to 100 ng/mL or higher, with clinical decision thresholds commonly set at 0.25 ng/mL (low probability of bacterial infection) and 0.5 ng/mL (high probability warranting antibiotics). Analytical turnaround ranges from 18–30 minutes for dedicated immunoassay modules to 60–90 minutes when batched on high-throughput platforms. Point-of-care formats have emerged for rapid bedside assessment: the Abionic abioSCOPE device measures pancreatic stone protein (PSP) from whole blood in approximately 5 minutes using nanofluidic immunoassay technology, cleared via 510(k) K240041. Multi-marker approaches combine proteins with different kinetic profiles—for example, the MeMed BV assay (510(k) K210254 and subsequent clearances K222332 and K230944) integrates TRAIL, IP-10, and CRP measurements to distinguish bacterial from viral infection, while the DiaSorin LIAISON MeMed BV (510(k) K213936) provides the same panel on an automated platform. The Prenosis Sepsis ImmunoScore, authorized via De Novo DEN230036, combines 22 host-response biomarkers with clinical variables using a machine-learning algorithm to generate a sepsis probability score, representing a hybrid approach that bridges M6 protein biomarkers with M11 AI/ML multimodal scoring. Assay calibration typically employs recombinant protein standards traceable to international reference materials where available; PCT assays reference the BRAHMS PCT-LIA standard. Quality control requires daily or per-run verification with bi-level controls spanning clinically relevant concentration ranges.

Operational footprint

Deployment requirements vary substantially across platform tiers. High-throughput laboratory analyzers (Roche cobas, Beckman Coulter Access, bioMérieux VIDAS, DiaSorin LIAISON) require 15–50 square feet of bench space, dedicated electrical circuits, climate-controlled environments, and integration with laboratory information systems; these instruments typically process 50–200 immunoassay tests per hour and support continuous random-access operation. Reagent storage demands 2–8°C refrigeration with shelf lives of 4–12 weeks after opening. Staffing models assume existing clinical laboratory technologist coverage, adding minimal incremental burden when PCT or other sepsis markers join existing immunoassay menus. Point-of-care devices like the Abionic abioSCOPE occupy minimal footprint (benchtop or portable) and require only brief operator training, but sacrifice throughput for accessibility—single-sample processing suits emergency department triage or ICU bedside use rather than high-volume central laboratory workflows. The commercial landscape includes over 100 companies developing or marketing protein biomarker assays for sepsis applications, indicating robust adoption infrastructure and competitive supply chains. Reagent costs range from $8–15 per PCT test on high-volume analyzers to $25–50 for specialized markers or point-of-care formats; capital equipment ranges from $50,000–150,000 for mid-tier immunoassay analyzers to $5,000–15,000 for dedicated point-of-care readers. Reimbursement under CPT 84145 (procalcitonin) provides approximately $25–35 per test, while novel multi-marker panels may require proprietary PLA codes with variable payer coverage.

Maturity signals

Procalcitonin immunoassays represent the most mature segment, with multiple FDA-cleared platforms from Roche (510(k) K160729), bioMérieux (510(k) K160911 and earlier K071146), Beckman Coulter (510(k) K192271 and K222996), DiaSorin (510(k) K173683), Fujirebio (510(k) K172713), Diazyme (510(k) K162297), and DiaSys (510(k) K242294). Clinical evidence supporting PCT-guided antibiotic stewardship spans dozens of randomized trials demonstrating reduced antibiotic exposure without adverse outcomes, embedded in Surviving Sepsis Campaign guidelines. The patent landscape shows concentrated activity among established diagnostics manufacturers, with BRAHMS GmbH (now part of Thermo Fisher) holding foundational PCT intellectual property and maintaining the largest patent portfolio in this cluster. Emerging biomarker developers including Sphingotec (adrenomedullin, proenkephalin), MeMed (TRAIL/IP-10/CRP combination), and Abionic (pancreatic stone protein) have built focused patent estates around novel markers and assay configurations. Clinical trials continue to expand the evidence base: Sphingotec has completed studies on adrenomedullin for sepsis outcome prediction (NCT02393781) and proenkephalin for acute kidney injury detection (NCT04019314), while Abionic has completed multiple validation studies for PSP (NCT03474809, NCT05627076, NCT04105699, NCT05849935, NCT04797117). The participation pattern shows mechanism-aligned innovation with moderate competitive density—ten unique assignees across 119 patents—suggesting established players dominate but white space remains for novel biomarker combinations and point-of-care implementations.

Challenges

Protein biomarkers inherently measure host response rather than pathogen presence, creating fundamental limitations: elevated PCT occurs in non-infectious inflammatory states (major surgery, trauma, burns, cardiogenic shock), while immunocompromised patients may fail to mount detectable responses despite active infection. Kinetic profiles constrain clinical utility—PCT rises 4–6 hours after bacterial infection onset and peaks at 24–48 hours, making it suboptimal for hyperacute presentations where M2 or M3 pathogen detection would provide faster actionable information. Single-marker approaches lack specificity for distinguishing bacterial from viral infection, driving development of multi-marker panels like MeMed BV, but these add cost and complexity. Unlike genotypic resistance detection (M8) or phenotypic AST (M7), protein biomarkers provide no information about antimicrobial susceptibility, requiring parallel testing for definitive therapy guidance. Point-of-care formats sacrifice analytical precision for accessibility—coefficient of variation may reach 15–20% versus 5–8% for laboratory analyzers—potentially affecting clinical decision thresholds. Standardization remains incomplete: different PCT assays show 10–20% inter-method variability despite calibration to common standards, complicating interpretation when patients transfer between institutions. Novel biomarkers face adoption barriers including limited clinical evidence, absence from treatment guidelines, uncertain reimbursement, and clinician unfamiliarity. The regulatory pathway for multi-marker algorithmic scores (exemplified by Prenosis Sepsis ImmunoScore requiring De Novo classification) demands more extensive clinical validation than single-analyte assays, extending development timelines and costs.

← Back to what’s inside this report